Similar to patritumab, the efficacy of other anti-HER3 monoclonal antibodies was detected preclinically in some cancer cells across various cancers, especially in those with a high expression level of heregulin, but the clinical trials conducted for these antibodies could not find any clinical significance in NSCLC, BC, colon, and even HNSCC, which has the highest expression level of heregulin among malignancies [24]. This evidence concerns the gene NRG1 and non-small cell lung carcinoma.